Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 141

Sort by

Sort Order Select

Journal Articles

Prognostic significance of clinical risk models and genomic alterations in Waldenström macroglobulinemia before or after BTK inhibitor era

Weihao Chen, Yuting Yan, Ying Yu, Yuxi Li, Xiong Wenjie, Xinyi Zhang, Tingyu Wang, Wei LIU, Weiwei Sui, Zhen Yu, Mu Hao, Gang An, Dehui Zou, Lugui Qiu, Shuhua Yi

Blood (2025) 146 (Supplement 1): 3593.

https://doi.org/10.1182/blood-2025-3593

Published: 2025

Journal Articles

Ixazomib combined with daratumumab-based regimens as first-line therapy for transplant-ineligible patients with newly diagnosed multiple myeloma: A real-world historical database analysis from China

Jieqiong Zhou, Gang An, Yuntong Liu, Wenqiang Yan, Chenxing Du, Shuhui Deng, Weiwei Sui, Yan Xu, Lugui Qiu

Blood (2025) 146 (Supplement 1): 8142.

https://doi.org/10.1182/blood-2025-8142

Published: 2025

Journal Articles

Dynamic changes in cytogenetic abnormalities during treatment predict long-term outcomes in multiple myeloma

Jieqiong Zhou, Yuntong Liu, Gang An, Lugui Qiu

Blood (2025) 146 (Supplement 1): 7542.

https://doi.org/10.1182/blood-2025-7542

Published: 2025

Journal Articles

Delayed and sustained minimal residual disease response predictsfavorable outcomes in newly diagnosed multiple myeloma

Jieqiong Zhou, Yating Li, Gang An, Lugui Qiu

Blood (2025) 146 (Supplement 1): 7536.

https://doi.org/10.1182/blood-2025-7536

Published: 2025

Journal Articles

BCMA CAR T-cell therapy in newly diagnosed transplant-ineligible multiple myeloma: An open label, single-arm, phase 2 study (CAREMM-001)

Wenqiang Yan, Chenxing Du, Hesong Zou, Shuaishuai Zhang, Shuhui Deng, Yan Xu, Shuhua Yi, Dehui Zou, Lugui Qiu, Gang An

Blood (2025) 146 (Supplement 1): 2293.

https://doi.org/10.1182/blood-2025-2293

Published: 2025

Journal Articles

QLS4131, a next-generation GPRC5D×BCMA×CD3 trispecific T-cell engager, in patients with relapsed/refractory multiple myeloma (RRMM): Initial results of a first-in-human Phase Ⅰa study

Gang An, Yafei Wang, Hui Guo, Wanhong Zhao, Xiaobing Huang, Zhongjun Xia, Jian Chen, Xianlin Duan, Zeyu Yang, Xiaoyan Kang, Lugui Qiu

Blood (2025) 146 (Supplement 1): 5831.

https://doi.org/10.1182/blood-2025-5831

Published: 2025

Journal Articles

Treatment outcomes in patients with newly diagnosed multiple myeloma receiving ixazomib as initial therapy: A retrospective, observational, real-world historical database analysis from China

Gang An, Jieqiong Zhou, Yuntong Liu, Wenqiang Yan, Chenxing Du, Shuhui Deng, Weiwei Sui, Yan Xu, Lugui Qiu

Blood (2025) 146 (Supplement 1): 2246.

https://doi.org/10.1182/blood-2025-2246

Published: 2025

Journal Articles

Dynamic evolution of minimal residual disease and normal plasma cells following autologous stem cell transplantation in multiple myeloma

Qirui Bai, Wenqiang Yan, Xiaoqi Qin, Lugui Qiu, Gang An

Blood (2025) 146 (Supplement 1): 2241.

https://doi.org/10.1182/blood-2025-2241

Published: 2025

Journal Articles

BCMA CAR T-cell therapy in newly diagnosed primary plasma cell leukemia ineligible for transplantation: An open label, single-arm, phase 2 study (CAREMM-002)

Wenqiang Yan, Chenxing Du, Hesong Zou, Shuaishuai Zhang, Shuhui Deng, Lugui Qiu, Gang An

Blood (2025) 146 (Supplement 1): 257.

https://doi.org/10.1182/blood-2025-257

Published: 2025

Journal Articles

LILRB4 drives proinflammatory cytokine secretion in multiple myeloma to promote the immune-cell dysfunction via the generation of myeloid-derived suppressive cells

Lanting Liu, Hao Sun, Yijie Wang, Xiyue Sun, Gang An, Lugui Qiu, Mu Hao

Blood (2025) 146 (Supplement 1): 5695.

https://doi.org/10.1182/blood-2025-5695

Published: 2025

Journal Articles

Metabolomics profiling and machine learning prediction of efficacy and prolonged cytopenia in patients with large B-cell lymphoma undergoing CAR-T therapy

Hesong Zou, Chen Jia, Wei LIU, Huimin Liu, Yi Wang, Yan Xu, Shuhua Yi, Gang An, Lugui Qiu, Dehui Zou

Blood (2025) 146 (Supplement 1): 1938.

https://doi.org/10.1182/blood-2025-1938

Published: 2025

Journal Articles

Circulating tumor plasma cells as an independent prognostic marker in newly diagnosed multiple myeloma: Clinical correlation and immunophenotypic insights

Yating Li, Yuntong Liu, Jieqiong Zhou, Wenqiang Yan, Jian Cui, Jingyu Xu, Chenxing Du, Shuhui Deng, Yan Xu, Lugui Qiu, Gang An

Blood (2025) 146 (Supplement 1): 5761.

https://doi.org/10.1182/blood-2025-5761

Published: 2025

Journal Articles

Preliminary analysis of orelabrutinib combined with obinutuzumab in the treatment of marginal zone lymphoma (Orion Study)

Rui Lv, Tingyu Wang, Yuting Yan, Tengteng Yu, Xiong Wenjie, Ying Yu, Qi Wang, Shuaishuai Zhang, Hesong Zou, Shuhui Deng, Yan Xu, Dehui Zou, Liang Huang, Gang An, Lugui Qiu, Shuhua Yi

Blood (2025) 146 (Supplement 1): 5379.

https://doi.org/10.1182/blood-2025-5379

Published: 2025

Journal Articles

Preliminary efficacy and safety of golidocitinib in relapsed/refractory T cell and NK cell large granular lymphocyte leukemia

Ying Yu, Yuxi Li, Rui Cui, Tingyu Wang, Yin WU, Chenglu Yuan, Yuqing Chen, Huanling Zhu, Yuting Yan, Wenjie Xiong, Shuhui Deng, Gang An, Lugui Qiu, Shuhua Yi

Blood (2025) 146 (Supplement 1): 3648.

https://doi.org/10.1182/blood-2025-3648

Published: 2025

Journal Articles

MBS314, a GPRC5DxBCMAxCD3 trispecific antibody, in relapsed/refractory multiple myeloma (RRMM): Updated results from a Phase 1 dose escalation study

Gang An, Wenming Chen, Wen Gao, Ting Yang, Lijie Xing, Kaihong Xu, Yan Zhang, Tong Xu, Min Wei, Feng Li, Guojin Wu, Jinying Ning, Lugui Qiu

Blood (2025) 146 (Supplement 1): 2274.

https://doi.org/10.1182/blood-2025-2274

Published: 2025

Journal Articles

Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: The first real-world data from a single Chinese center

Blood (2025) 146 (Supplement 1): 4074.

https://doi.org/10.1182/blood-2025-4074

Published: 2025

Journal Articles

CAC-MM-001: Anti-BCMA CAR-T therapy followed by autologous stem cell transplantation and second CAR-T (CART-ASCT-CART2) in newly diagnosed multiple myeloma patients with P53 gene abnormalities.

Yuntong Liu, Weiwei Sui, Lugui Qiu, Gang An

Blood (2025) 146 (Supplement 1): 4068.

https://doi.org/10.1182/blood-2025-4068

Published: 2025

Journal Articles

CART–ASCT–CART2 sandwich regimen as frontline therapy: A phase II trial in patients with primary plasma cell leukemia

Jingyu Xu, Qirui Bai, Yuntong Liu, Wenqiang Yan, Shuaishuai Zhang, Wenyang Huang, Chenxing Du, Lugui Qiu, Gang An

Blood (2025) 146 (Supplement 1): 4067.

https://doi.org/10.1182/blood-2025-4067

Published: 2025

Journal Articles

Updated results of a first-in-human, Phase Ⅰa/Ⅰb study of QLS32015 (GPRC5D×CD3) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Gang An, Baijun Fang, Xiaobing Huang, Yan Xu, Fei Li, Zhen Cai, Xiaojing Yan, Xianqi Feng, Wuping Li, Xiangmin Tong, Zengjun Li, Yuzhang Liu, Feifei Che, Xin'ai Yang, Xianlin Duan, Peng Shao, Xiaoyan Kang, Lugui Qiu

Blood (2025) 146 (Supplement 1): 4049.

https://doi.org/10.1182/blood-2025-4049

Published: 2025

Journal Articles

PHF19 inhibition increases IMiDs sensitivity by epigenetically regulating IRF4 and MYC in multiple myeloma

Xiyue Sun, Tengteng Yu, Teng Fang, Hao Sun, Xiaoyu Zhang, Zhen Yu, Lanting Liu, Gang An, Lugui Qiu, Mu Hao

Blood (2025) 146 (Supplement 1): 2164.

https://doi.org/10.1182/blood-2025-2164

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Prognostic significance of clinical risk models and genomic alterations in Waldenström macroglobulinemia before or after BTK inhibitor era

Ixazomib combined with daratumumab-based regimens as first-line therapy for transplant-ineligible patients with newly diagnosed multiple myeloma: A real-world historical database analysis from China

Dynamic changes in cytogenetic abnormalities during treatment predict long-term outcomes in multiple myeloma

Delayed and sustained minimal residual disease response predictsfavorable outcomes in newly diagnosed multiple myeloma

BCMA CAR T-cell therapy in newly diagnosed transplant-ineligible multiple myeloma: An open label, single-arm, phase 2 study (CAREMM-001)

QLS4131, a next-generation GPRC5D×BCMA×CD3 trispecific T-cell engager, in patients with relapsed/refractory multiple myeloma (RRMM): Initial results of a first-in-human Phase Ⅰa study

Treatment outcomes in patients with newly diagnosed multiple myeloma receiving ixazomib as initial therapy: A retrospective, observational, real-world historical database analysis from China

Dynamic evolution of minimal residual disease and normal plasma cells following autologous stem cell transplantation in multiple myeloma

BCMA CAR T-cell therapy in newly diagnosed primary plasma cell leukemia ineligible for transplantation: An open label, single-arm, phase 2 study (CAREMM-002)

LILRB4 drives proinflammatory cytokine secretion in multiple myeloma to promote the immune-cell dysfunction via the generation of myeloid-derived suppressive cells

Metabolomics profiling and machine learning prediction of efficacy and prolonged cytopenia in patients with large B-cell lymphoma undergoing CAR-T therapy

Circulating tumor plasma cells as an independent prognostic marker in newly diagnosed multiple myeloma: Clinical correlation and immunophenotypic insights

Preliminary analysis of orelabrutinib combined with obinutuzumab in the treatment of marginal zone lymphoma (Orion Study)

Preliminary efficacy and safety of golidocitinib in relapsed/refractory T cell and NK cell large granular lymphocyte leukemia

MBS314, a GPRC5DxBCMAxCD3 trispecific antibody, in relapsed/refractory multiple myeloma (RRMM): Updated results from a Phase 1 dose escalation study

Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: The first real-world data from a single Chinese center

CAC-MM-001: Anti-BCMA CAR-T therapy followed by autologous stem cell transplantation and second CAR-T (CART-ASCT-CART2) in newly diagnosed multiple myeloma patients with P53 gene abnormalities.

CART–ASCT–CART2 sandwich regimen as frontline therapy: A phase II trial in patients with primary plasma cell leukemia

Updated results of a first-in-human, Phase Ⅰa/Ⅰb study of QLS32015 (GPRC5D×CD3) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

PHF19 inhibition increases IMiDs sensitivity by epigenetically regulating IRF4 and MYC in multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only